Market Executive Summary

REPORT HIGHLIGHT
The Fluorescent In Situ Hybridization Probe (FISH Probe) Market is estimated to represent a global market of USD 780.2 million by 2017 with growth rate of 8.3%. FISH probes are primarily used in clinical diagnostics for detection of genetic abbreviation in chromosomes. Owing to their accuracy and sensitivity for disease diagnosis, FISH techniques are widely used diagnostic tool in research laboratories and clinical diagnostic laboratories.
FISH probes are also used for detection of microorganisms causing infections. Increasing prevalence of cancer, inflammatory, and chronic diseases associated with cytogenetic modifications. According to the estimates of the World Health Organization, in 2012, worldwide cancer incidences (cases per year) were nearly 14.1 million, which included 7.4 million male and 6.7 million female patients.
FISH is also useful in differentiating between cancer sub types. Additionally, increasing prevalence of infectious diseases is expected to boost the usage of FISH probes for detection of infectious bacteria. Technological advancements in FISH technique such as Flow-FISh and multiplex FISH are expected to further incline the growth of FISH probe market. Regulatory bodies such as the U.S. FDA and European CE have developed stringent guidelines for manufacturing and marketing of FISH related products, leading to hamper the market growth.
The global FISH probe market is segmented in terms of RNA types, end use, application, and technology. In terms of end use the market is divided into clinical, research and companion diagnostics. In 2017, clinical application segment recorded USD 267.8 million and is expected to dominate the market. mRNA AND miRNA are the types of RNA segment.
Whereas, application segment is categorized as cancer and genetic diseases diagnostics. Cancer is the largest revenue chunk for this market, captured USD 317.4 million in 2017 for FISH probe. Among application, breast cancer under cancer diagnosis is finding wider application for use of FISH probes. Efficacy and growing demand for FISH technique for the treatment of breast cancer drive the market growth of this segment.
Geographical regions studied in this report comprise of North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America and Europe recorded highest revenue of the global market. Introduction of technologically advanced probes for the purpose of enhanced accuracy, portability, and cost-effectiveness is expected to serve North America and Europe market as a high impact rendering driver.
Key companies such as BioDot Inc., Sigma Aldrich, Abnova, Abbott Laboratories, Agilent Technologies, Life Science Technologies and others are present in this market. Rising research activities coupled with strategic engagements supported the growth of these players. For example, in February 2013, Abbott entered into an agreement with BioView for the development of automated digital cell imaging software for ALK FISH probe test. There are more than dozens of other FISH probe segment reagents commercialized by Abbott and other established vendors for use in cancer and other disease diagnosis.
On other side, small scale companies also try to show their influence by developing novel FISH probe. For example, customized probes specific to 5S, 16S, and 23S rRNA are provided by companies such as RiboCon and SILVA. Database for rRNA probe designing are also available by SILVA.
The market size and forecast for each segment has been provided for the period 2014 to 2028, considering 2017 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2028 for every reported segment.
The years considered for the study are:
Historical Year ? 2014 & 2017
Base Year ? 2017
Estimated Year ? 2017
Projected Year ? 2028
TARGET AUDIENCE
Traders, Distributors, And Suppliers
Manufacturers
Hospitals
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY END USE
Clinical
Research
Companion Diagnostics
MARKET, BY RNA TYPE
mRNA
miRNA
MARKET, BY RNA TYPE
Cancer Diagnostics
Genetic Diseases
MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET, BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America